TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of T-cell chronic lymphocytic leukemia (T-CLL) or T-cell prolymphocytic leukemia (T-PLL)~* Previously untreated disease OR patient may have received up to 2 therapies~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Life expectancy \> 6 months~* No severe organ dysfunction~* No other concurrent or previous neoplasm~* No autoimmune hemolytic anemia or thrombocytopenia~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior fludarabine, mitoxantrone hydrochloride, cyclophosphamide, or alemtuzumab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female aged 18 years or over~2. Patients have been diagnosed with Rheumatoid Arthritis (RA) for at least 3 months~3. Patient has active RA~4. Patient has taken a stable dose of methotrexate for at least 3 months~Exclusion Criteria:~1. Patient has been previously treated with adalimumab~2. Patient has been previously treated or has ongoing treatment with prohibited medications~3. Patient has been immunised with a live or attenuated vaccine in past 4 weeks~4. Patient has positive result for HIV, HBV, HCV or TB infection~Other Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FKB327 (Type: EXPERIMENTAL): Patients will receive FKB327 40 mg every other week by subcutaneous injection. The treatment period will continue for 22 weeks.
- Humira® (Type: ACTIVE_COMPARATOR): Patients will receive Humira® 40 mg every other week by subcutaneous injection. The treatment period will continue for 22 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial Fibrillation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female and male patients aged 19 years or older (Korea) and aged 20 years or older (Taiwan)~* Diagnosis of NVAF~* Patients for whom the decision to initiate treatment with rivaroxaban is made as per physician's routine treatment practice~* Treatment naïve regarding stroke prevention for atrial fibrillation~* Signed informed consent~Exclusion Criteria:~* Contraindications for rivaroxaban according to the local market authorization/summary of product characteristics (SmPC)~* Patients participating in an investigational program with interventions outside of routine clinical practice

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment-naïve NVAF patients in Korea and Taiwan (Type: None): Patients will be followed according to routine medical practice and the frequency of visits and procedures will be performed under routine conditions. NVAF: Non-valvular atrial fibrillation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Must be at least 18 years of age~* Chronic plaque psoriasis (PSO) for at least 6 months prior to the Screening Visit~* Psoriasis Area Severity Index (PASI) \>=12 and body surface area (BSA) affected by PSO \>=10% and Investigator's Global Assessment (IGA) score \>=3 on a 5-point scale~* Subject is a candidate for systemic PSO therapy and/or phototherapy~* Female subject of child bearing potential must be willing to use highly effective method of contraception~Exclusion Criteria:~* Subject has an active infection (except common cold), a recent serious infection, or a history of opportunistic or recurrent chronic infections~* Subject has concurrent acute or chronic viral hepatitis B or C or human immunodeficiency virus (HIV) infection~* Subject has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or has current or history of nontuberculous mycobacterium (NTMB) infection~* Subject has any other condition, including medical or psychiatric, which, in the Investigator's judgment, would make the subject unsuitable for inclusion in the study~* Presence of active suicidal ideation or positive suicide behavior~* Presence of moderately severe major depression or severe major depression~* Subject has any active malignancy or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bimekizumab cohort (Type: EXPERIMENTAL): Subjects will receive bimekizumab for 52 weeks.
- Ustekinumab cohort (Type: ACTIVE_COMPARATOR): Subjects will receive ustekinumab (dose 1 or dose 2 depending on subjects weight) for 52 weeks. Placebo will be administered at pre-specified time points to maintain the blinding.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will receive placebo up to week 16 and bimekizumab starting at week 16 through week 52.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Treatment naïve participants~* Females must be either postmenopausal for at least 2 years or surgically sterile~* Males must be surgically sterile or practicing specific forms of birth control~* Chronic hepatitis C virus (HCV), genotype-1 infected participants~* Documented FibroTest score in combination with an Aspartate Aminotransferase to Platelet Ratio Index (APRI), or a liver biopsy within the last 12 months to document absence of cirrhosis~Exclusion Criteria:~* Pregnant or breastfeeding female~* Use of any medications contraindicated for use with pegylated interferon(pegIFN) or ribavirin (RBV) 2 weeks prior to study drug administration or 10 half-lives, whichever is longer~* Clinically significant cardiac, respiratory (except mild asthma), renal, gastrointestinal, hematologic, neurologic disease, or any uncontrolled medical illness or psychiatric disease or disorder~* Current or past clinical evidence of cirrhosis or bridging fibrosis~* Abnormal screening laboratory results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ABT-267 (5 mg) once daily + pegIFN/RBV (Type: EXPERIMENTAL): Participants were given 5 mg ABT-267 once daily in combination with pegylated interferon/ribavirin (pegIFN/RBV) for 12 weeks, followed by 36 weeks of pegIFN/RBV treatment alone. Pegylated interferon was dosed 180 µg subcutaneously once a week. Ribavirin was dosed 1000 or 1200 mg daily divided twice a day.
- ABT-267 (50 mg) once daily + pegIFN/RBV (Type: EXPERIMENTAL): Participants were given 50 mg ABT-267 once daily in combination with pegylated interferon/ribavirin (pegIFN/RBV) for 12 weeks, followed by 36 weeks of pegIFN/RBV treatment alone. Pegylated interferon was dosed 180 µg subcutaneously once a week. Ribavirin was dosed 1000 or 1200 mg daily divided twice a day.
- ABT-267 (200 mg) once daily + pegIFN/RBV (Type: EXPERIMENTAL): Participants were given 200 mg ABT-267 once daily in combination with pegylated interferon/ribavirin (pegIFN/RBV) for 12 weeks, followed by 36 weeks of pegIFN/RBV treatment alone. Pegylated interferon was dosed 180 µg subcutaneously once a week. Ribavirin was dosed 1000 or 1200 mg daily divided twice a day.
- Placebo + pegIFN/RBV (Type: PLACEBO_COMPARATOR): Participants were given matching placebo to ABT-267 once daily in combination with pegIFN/RBV for 12 weeks, followed by 36 weeks of pegIFN/RBV treatment alone. Pegylated interferon was dosed 180 µg subcutaneously once a week. Ribavirin was dosed 1000 or 1200 mg daily divided twice a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Coronavirus Disease 2019 (COVID-19) Antibody Plasma Research Study in Hospitalized Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age at least 18 years~2. Ability and willingness of participant or Legally Authorized Representative (LAR) to give written informed consent.~3. Laboratory confirmed diagnosis of infection with SARS-CoV-2 by PCR~4. Hospitalized for COVID-19 with one or more respiratory or gastrointestinal (GI) symptoms:~   * COVID-19 associated respiratory symptoms include but are not limited to: cough, shortness of breath, difficulty breathing, or sore throat~  * COVID-19 associated GI symptoms include but are not limited to: loss of taste, loss of sense of smell, diarrhea, nausea, or vomiting,~Note: Respiratory and GI symptoms other than those listed above, must be noted as acceptable and signed by study PI or designee.~Exclusion Criteria:~1. Receipt of pooled immunoglobulin in past 30 days~2. Current or prior enrollment in a SARS-CoV-2 antibody or T-cell therapeutic study.~   Note: Patients enrolled on other randomized controlled trials of pharmaceutical and/or non-pharmaceutical interventions for COVID and meeting eligibility criteria will not be excluded, as determined by study PI (or designee) on a case-by-case basis and as allowed by eligibility criteria of the other trials.~3. Contraindication to transfusion or history of prior reactions to transfusion blood products. This may include religious or cultural objections to receiving blood products and transfusions.~4. ABO-compatible titered plasma is not available~5. \> 10 days from noted COVID-related subjective or objective fever at randomization. Patients without subjective or objective fever, \> 10 days from symptom onset as determined by study PI.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- High-Titer (CCP1) (Type: EXPERIMENTAL): Within 8 days of COVID symptom onset and no more than 48 hours following hospitalization, participants will be randomized to and receive high-titer ABO-compatible convalescent COVID-19 plasma (CCP1) within 24 hours following random assignment.
- Standard-Titer (CCP2) (Type: ACTIVE_COMPARATOR): Within 8 days of COVID symptom onset and no more than 48 hours following hospitalization, participants will be randomized to and receive standard-titer ABO-compatible convalescent COVID-19 plasma (CCP2) within 24 hours following random assignment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RADAR Trial - Randomised Androgen Deprivation and Radiotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Histological confirmation of adenocarcinoma of the prostate in the three months prior to randomisation~* Gleason primary and secondary pattern reported. If the volume of tumour in biopsies is too small for the pathologist to allocate a secondary pattern, the primary pattern alone is sufficient.~* Primary tumour stage T2b - 4 (UICC 2002), or T2a providing biopsies demonstrate Gleason score 7 or more, and presenting PSA 10 or more~* PSA value obtained within one month of randomisation~* No evidence of lymphatic or haematogenous metastases, as determined by negative chest x-ray, CT scan of abdomen and pelvis, and bone scan in the 3 months prior to randomisation~* ECOG performance status 0 - 1~* No concurrent medical conditions likely to significantly reduce prospects of 5 year survival~* Patient accessible to follow up at intervals specified in protocol~* Written informed consent given (signed by both patient and investigator prior to randomisation)~Exclusion Criteria:~* Previous or concurrent malignancy within previous 5 years except for non-melanomatous skin cancer~* Prostatectomy~* Prior pelvic radiotherapy~* Prior hormone treatment for prostate cancer~* Inability to complete self administered QOL questionnaire~* Prior bisphosphonate therapy~* Serum creatinine \> 2 x ULN~* Osteoporosis resulting in \>30% loss in vertebral height in one or more thoraco-lumbar vertebrae~* Liver disease resulting in ALT or AST levels \>3 x ULN~* Prolonged continuous glucocorticoid therapy \> 10 mg/day of prednisone equivalent (\>6 months)~* Current treatment with bisphosphonate~* Inability to attend for follow-up at the Investigator's clinic

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): LH-RH analogue for 5 months prior to and during first month of radiation treatment (total 6 mths)
- B (Type: ACTIVE_COMPARATOR): LH-RH analogue for 5 months prior to and during first month of radiation treatment (total 6 months) + bisphosphonate therapy.
- C (Type: EXPERIMENTAL): LH-RH analogue as for arm A, but continued for further 12 months (total 18 months)
- D (Type: EXPERIMENTAL): LH-RH analogue as for arm A, but continued for further 12 months (total 18 months) + bisphosphonate therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Medicinal Nicotine for Preventing Stress Induced Craving and Withdrawal Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Smoking an average of at least 10 cigarette per day~* General good health~Exclusion Criteria:~* unstable medical or psychiatric conditions~* history of severe motion sickness~* women who are pregnant or breast feeding~The investigators will evaluate if there are other reasons why someone may not participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Nicotine Lozenge Immediately Prior to Stress task (Type: EXPERIMENTAL): Subjects will receive the nicotine lozenge immediately prior to the stress task at one laboratory session and after the stress task at the other laboratory session
- Nicotine lozenge 10 Minutes prior to Stress task (Type: EXPERIMENTAL): Subjects will receive the nicotine lozenge after the stress task during one laboratory session and immediately prior to the stress task at the other laboratory session
- Nicotine lozenge 20 minutes prior to Stress task (Type: EXPERIMENTAL): Subjects will receive the nicotine lozenge after the stress task during one laboratory session and 10 minutes prior to the stress task at the other laboratory session
- Nicotine Lozenge 30 minutes prior to stress taks (Type: EXPERIMENTAL): Subjects will receive the nicotine lozenge 10 minutes prior to the stress task during one laboratory session and after the stress task at the other laboratory session

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Swine Flu (Novel Influenza A H1N1) Vaccine Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* baby or child aged between 6 months to 12 years of age (i.e., to day before 13th birthday)~* for whom a parent/legal guardian has given written informed consent after the nature of the study has been explained~* available for all the visits scheduled in the study~* willingness to complete all study procedures~Exclusion Criteria:~* History of any vaccine against novel influenza A strain H1N1 (based on verbal confirmation from parent/guardian)~* Previous laboratory confirmed case of novel influenza A strain H1N1 or treatment with oseltamivir or zanamivir for novel influenza A strain H1N1 (n.b. a child commenced on treatment with oseltamivir or zanamivir for novel influenza A strain H1N1 whose treatment was stopped following negative microbiological tests for H1N1 on nasal swabs would be allowed to enrol in the study\]~* History of severe allergic reaction after previous vaccinations or hypersensitivity to any H1N1 vaccine component~* Current egg allergy~* Known or suspected impairment/alteration of the immune system~* Disorders of coagulation~* Immunosuppressive therapy, use of systemic corticosteroids for more than 1 week within the 3 months prior to enrollment~* Receipt of blood, blood products and/or plasma derivatives or any immunoglobulin preparation within 3 months prior to enrollment~* Intent to immunize with any other vaccine(s) against novel influenza A strain H1N1 throughout the study period~* Participation in another clinical trial of an investigational medical product~* Any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives. Children with chronic, stable medical illnesses that do not result in immunosuppression (e.g., cerebral palsy, epilepsy, cystic fibrosis, congenital heart disease) will be allowed to participate in the study, unless these conditions will in some way interfere with the completion of study procedures. Children with conditions that may alter the immune response to vaccines (e.g., Trisomy 21) or will affect the ability to accurately describe adverse events (e.g., children over 5 years of age but with severe learning difficulties) will be excluded

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- Groups A1 and A2 (Type: EXPERIMENTAL): Baxter vaccine
- Groups B1 and B2 (Type: EXPERIMENTAL): GSK vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Chronic Hepatitis C Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females must be post-menopausal for at least 2 years or surgically sterile or practicing specific forms of birth control~* Chronic hepatitis C, genotype 1-infection and HCV RNA level greater than 10,000 IU/mL at screening~* Subject has never received antiviral treatment for hepatitis C infection~* No evidence of liver cirrhosis~Exclusion Criteria:~* Positive screen for drugs or alcohol~* Significant sensitivity to any drug~* Use of contraindicated medications within 2 weeks of dosing~* Certain predefined abnormal laboratory tests~* Positive hepatitis B surface antigen or anti-human immunodeficiency virus antibody

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ABT-450/r/ABT-267 and ABT-333, plus RBV (Type: EXPERIMENTAL): Double-blind ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
- Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV (Type: EXPERIMENTAL): Double-blind placebo for 12 weeks, followed by open-label ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete